Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paul S Martin, MD, Isaac C Jenkins, MS, Theodore A Gooley, PhD, Damian J Green, MD, John M Pagel, MD PhD, Sally J Lundberg, RN, Lacey M Hedine, Joseph G Rajendran, MD, Andrew T Shields, MD, Darrell R Fisher, PhD, David G Maloney, MD PhD, Frederick R Appelbaum, MD, Ryan D Cassaday, MD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2015) 126 (23): 5502.

https://doi.org/10.1182/blood.V126.23.5502.5502

Published: 2015

Journal Articles

Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation

Yang Liu, MD, Elise A. Chong, MD, Sigrid Berg, MD, Abass Alavi, MD, Rodolfo Perini, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Anthony Mato, MDMSCE, Stephen J. Schuster, MD

Blood (2014) 124 (21): 5471.

https://doi.org/10.1182/blood.V124.21.5471.5471

Published: 2014

Journal Articles

131 I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission

Mazyar Shadman, MD, MPH, Ajay K. Gopal, MD, Pamela S. Becker, MD, PhD, David G. Maloney, MD, PhD, Barbara Pender, Andrei R. Shustov, MD, Raya Mawad, MD, Britt Kammerer, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 1644.

https://doi.org/10.1182/blood.V122.21.1644.1644

Published: 2013

Journal Articles

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Ajay K. Gopal, MD, Ted A. Gooley, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2012) 120 (21): 811.

https://doi.org/10.1182/blood.V120.21.811.811

Published: 2012

Journal Articles

Incidence and Characteristics of Therapy-Related Myeloid Neoplasms in Patients with Non-Hodgkins Lymphoma Treated with Radioimmunotherapy

Salman Waheed, MD, Iva Ferreira, MD, Deborah A. Katz, MD, Reem Karmali, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD

Blood (2012) 120 (21): 4924.

https://doi.org/10.1182/blood.V120.21.4924.4924

Published: 2012

Journal Articles

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Daniel Lebovic, MD, Mark S. Kaminski, MD, Tara B. Anderson, Kristen Detweiler-Short, Kent A. Griffith, Terri L. Jobkar, BSN, Malathi Kandarpa, PhD, Andrzej Jakubowiak, MD, PhD

Blood (2012) 120 (21): 1854.

https://doi.org/10.1182/blood.V120.21.1854.1854

Published: 2012

Journal Articles

90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients.

Louis Terriou, MD, Hanane Gasmi, Salomon Manier, MD, Isabelle Plantier, MD, Marc Wetterwald, MD, PhD, Pauline lionne-Huyghe, MD, Daniela Robu, MD, Sabine Tricot, MD, Ibrahim Yakoub-Agha, MD, PhD, Nicolas Simon, PhD, Pascal Odou, PhD, Franck Morschhauser, MD, PhD

Blood (2012) 120 (21): 2726.

https://doi.org/10.1182/blood.V120.21.2726.2726

Published: 2012

Journal Articles

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD, Ted Gooley, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 663.

https://doi.org/10.1182/blood.V118.21.663.663

Published: 2011

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)

Adam C. Rose, Gia Garrett, Miray Seward, Pareen J Shenoy, MBBS, MPH, Roy A Kucuk, Hannah Doksansky, Christopher R Flowers, MD

Blood (2011) 118 (21): 101.

https://doi.org/10.1182/blood.V118.21.101.101

Published: 2011

Journal Articles

Fractionated 90 y Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Timothy M Illidge, MD, PhD, Ruth Pettengell, MD, Michael Bayne, MD, Steven Le Gouill, MD, PhD, Andrew Bates, MD, John Radford, MD, Jill Tipping, PhD, Maureen Zivanovic, PhD, Françoise kraeber-Bodere, MD, Emmanuel Malek, PhD, Huglo Damien, MD, Franck Morschhauser, MD, PhD

Blood (2011) 118 (21): 102.

https://doi.org/10.1182/blood.V118.21.102.102

Published: 2011

Journal Articles

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Ayad Al-Katib, MD, FACP, Mary Mandziara, NP, Susan Szpunar, PhD, Kleanthe Kolizeras, BS, Mary Steigelman, RN, John Kalabat, MD, Zyad Kafri, MD

Blood (2011) 118 (21): 4991.

https://doi.org/10.1182/blood.V118.21.4991.4991

Published: 2011

Journal Articles

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Julie M Vose, MD, Shelly L Carter, ScD, Linda J Burns, MD, Ernesto Ayala, MD, Oliver W. Press, MD, PhD, Craig H. Moskowitz, MD, Edward A. Stadtmauer, MD, Shin Mineishi, MD, Richard F. Ambinder, Timothy S. Fenske, MD, Mary M. Horowitz, MD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 661.

https://doi.org/10.1182/blood.V118.21.661.661

Published: 2011

Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC

Blood (2010) 116 (21): 4916.

https://doi.org/10.1182/blood.V116.21.4916.4916

Published: 2010

Journal Articles

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Jonathan W. Friedberg, MD, Joseph M Unger, Ph.D., W. Richard Burack, Ajay K Gopal, MD, Michael LeBlanc, Ph.D., Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2010) 116 (21): 590.

https://doi.org/10.1182/blood.V116.21.590.590

Published: 2010

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

Journal Articles

Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin's Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study.

Sandra J Horning, MD, Anas Younes, MD, Donald Podoloff, MD, Thierry J Horner, PhD, Vanessa C Williams, MS, Christina Vleisides, Michael Goris, MD, PhD

Blood (2009) 114 (22): 2732.

https://doi.org/10.1182/blood.V114.22.2732.2732

Published: 2009

NARROW

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation

131 I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Incidence and Characteristics of Therapy-Related Myeloid Neoplasms in Patients with Non-Hodgkins Lymphoma Treated with Radioimmunotherapy

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients.

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)

Fractionated 90 y Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin's Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only